Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK NON-CONTROLLING INTERESTS AND STOCKHOLDERS' (DEFICIT) EQUITY

v3.6.0.2
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK NON-CONTROLLING INTERESTS AND STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)
Total
Noncontrolling Interest [Member]
Total Convertible Preferred Stock and Non-Controlling Interests [Member]
Common Stock [Member]
Common Stock Issuable [Member]
Additional Paid In Capital [Member]
Stockholder Note Receivable [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Series A Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Balance at Dec. 31, 2014 $ (46,806,801) $ 6,780,588 $ 43,189,254 $ 2,018   $ 10,055,613 $ (58,824) $ 56,544 $ (56,862,152) $ 254,525 $ 6,926,180 $ 5,745,127 $ 23,482,834  
Balance (in shares) at Dec. 31, 2014       201,787           2,483,692 8,073,508 3,351,156 19,557,392  
Stock-Based Compensation 780,293         780,293                
Issuance of Common Stock in Offering, Net of Offering Costs 4,099,500     $ 6,833   4,092,667                
Issuance of Common Stock in Offering, Net of Offering Costs (in shares)       683,250                    
Expenses related to initial public offering (1,373,858)         (1,373,858)                
Asset valuation adjustment at Jade Therapeutics acquisition (1,254,338)         (1,254,338)                
Conversion of Series A Preferred Stock 36,408,666   (36,408,666) $ 45,678   36,362,988       $ (254,525) $ (6,926,180) $ (5,745,127) $ (23,482,834)  
Conversion of Series A Preferred Stock (in shares)       4,567,782           (2,483,692) (8,073,508) (3,351,156) (19,557,392)  
Conversion of promissory notes to common stock at $4.20 per share 3,532,694     $ 8,660   3,524,034                
Conversion of promissory notes to common stock at $4.20 per share (in shares)       866,056                    
Beneficial conversion feature on conversion of Notes upon the IPO 1,663,873         1,663,873                
Exercise of Common Stock Options 26,826     $ 268   26,558                
Exercise of Common Stock Options (in shares)       26,799                    
Exercise of common warrants upon initial public offering 0     $ 97   (97)                
Exercise of common warrants upon initial public offering (in shares)       9,748                    
Conversion of Non-Controlling Interest to Common Stock 6,818,732 (6,818,732) (6,818,732)     6,818,732                
Reclassification of previously issued warrant liability to stockholders' equity 79,930         79,930                
Issuance of restricted stock 444,394     $ 1,254   443,140                
Issuance of restricted stock (in shares)       125,412                    
Adjustment for Fractional Shares       (17)                    
Issuance of Common Stock in Offering, Net of Offering Costs 10,001,760     $ 11,765   9,989,995                
Issuance of Common Stock in Offering, Net of Offering Costs (in shares)       1,176,470                    
Foreign Currency Translation Adjustment 58,244 32,967 32,967         58,244            
Net Loss Attributable to Common Stockholders (16,615,157) 5,177 5,177           (8,393,149)          
Balance at Dec. 31, 2015 6,086,766 $ 0 $ 0 $ 76,573 $ 0 71,209,530 (58,824) 114,788 (65,255,301) $ 0 $ 0 $ 0 $ 0 $ 0
Balance (in shares) at Dec. 31, 2015       7,657,287 0         0 0 0 0 0
Stock-Based Compensation 510,995         510,995                
Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition 2,909,766     $ 6,891 $ 291,536 2,611,339                
Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition (in shares)       689,157 76,571                  
Issuance of Holdback Shares from the Jade Acquisition 0     $ 227 $ (86,329) 86,102                
Issuance of Holdback Shares from the Jade Acquisition (in shares)       22,674 (22,674)                  
Forfeiture of Holdback Shares from the Jade Acquisition 0       $ (205,207) 205,207                
Forfeiture of Holdback Shares from the Jade Acquisition (in shares)         (53,897)                  
Issuance of Common Stock in Offering, Net of Offering Costs 668,437     $ 4,410   664,027                
Issuance of Common Stock in Offering, Net of Offering Costs (in shares)       441,000                    
Issuance of Series A Preferred Stock, Net of Offering Costs 2,776,447         2,776,419               $ 28
Issuance of Series A Preferred Stock, Net of Offering Costs (in shares)                           2,777
Conversion of Series A Preferred Stock 0     $ 12,340   (12,312)               $ (28)
Conversion of Series A Preferred Stock (in shares)       1,234,000                   (2,777)
Exercise of Common Stock Options 56,206     $ 868   55,338                
Exercise of Common Stock Options (in shares)       86,765                    
Foreign Currency Translation Adjustment 5,399             5,399            
Net Loss Attributable to Common Stockholders (13,343,437)               (13,343,437)          
Balance at Dec. 31, 2016 $ (329,421)     $ 101,309 $ 0 $ 78,106,645 $ (58,824) $ 120,187 $ (78,598,738)         $ 0
Balance (in shares) at Dec. 31, 2016       10,130,883 0                 0